prednisone and Thrombocytopenia studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research Excerpts

Excerpt	Relevance	Reference
"Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation."	9.19	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. ( Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R, 2014)
"The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)."	9.16	Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. ( Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2012)
"Initial analysis of the combination melphalan, prednisone, plus lenalidomide (MPR) showed significant antimyeloma activity in patients with untreated multiple myeloma, with neutropenia and thrombocytopenia as the most frequent side effects."	9.14	Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. ( Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB, 2009)
"To evaluate the effect of prednisone alone, compared with a combination of prednisone and vincristine, on platelet counts in bleeding dogs with severe primary immune-mediated thrombocytopenia (IMT)."	9.10	Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs. ( Callan, MB; Giger, U; Hughes, D; Rozanski, EA; Sanders, N, 2002)
"Results of previous studies have suggested that transplantation-related mortality among patients with chronic graft-versus-host disease (GVHD) may be reduced by combined treatment with cyclosporine (CSP) and prednisone rather than by prednisone alone."	9.10	Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. ( Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP, 2002)
"Our study assessed the factors that predispose renal transplant recipients to the occurrence of thrombocytopenia and leukopenia, as well as the severity and the time- and concentration-dependence of these side-effects, after administration of sirolimus (SRL) in combination with a cyclosporine (CsA) and prednisone (Pred) regimen."	9.09	Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. ( Hong, JC; Kahan, BD, 2000)
"The objective was to assess the efficacy of therapy with danazol in refractory immune thrombocytopenia associated with different rheumatic diseases."	9.08	Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. ( Blanco, R; González-Gay, MA; Martinez-Taboada, VM; Rodriguez-Valverde, V; Sanchez-Andrade, A, 1997)
"Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)."	9.05	Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982)
"A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0."	9.05	Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982)
"The aim of the present study was to investigate the relationship between hypothyroidism and thrombocytopenia in hepatitis B-related compensatory liver cirrhosis and to determine whether treatment with levothyroxine and prednisone is superior in a multicenter, open-label, observational study in China."	7.88	Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. ( Feng, R; Fu, H; Huang, X; Jiang, H; Jiang, Q; Liu, H; Liu, K; Lu, J; Niu, T; Wang, H; Wang, J; Wang, X; Xie, Y; Xu, L; Xue, J; Zhang, X, 2018)
" Her major chronic illness was immune thrombocytopenic purpura (ITP) for which she had been treated with prednisone therapy for the past 15 years."	7.80	From prednisone to pylori: a case of Helicobacter pylori-induced chronic immune thrombocytopenia. ( Hill, LJ; Tung, EE, 2014)
"A total of 18 patients with newly diagnosed/untreated MM and renal insufficiency (GFR < 35 ml/min) were treated with bendamustine, prednisone, and bortezomib (BPV)."	7.78	Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. ( Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T, 2012)
"We report that the use of alternate-day cyclosporine and prednisone improved the clinical course of a 6-year-old child with severe Evans syndrome."	7.69	Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone. ( Manno, CS; Rackoff, WR, 1994)
"Azathioprine, a thiopurine antimetabolite used in the treatment of immune-mediated thrombocytopenia in human beings and dogs, was used in 2 cases of immune-mediated thrombocytopenia in horses that failed to respond to corticosteroid therapy alone."	7.68	Azathioprine for treatment of immune-mediated thrombocytopenia in two horses. ( Beech, J; Cudd, TA; Gardner, SY; Humber, KA; Palmer, JE; Sommer, MM, 1991)
"We describe a patient with scleroderma who developed immune thrombocytopenia secondary to diclofenac on 2 occasions."	7.68	Diclofenac induced immune thrombocytopenia. ( Epstein, M; Stein, H; Vickars, L, 1990)
"An 81-year-old female developed marked thrombocytopenia associated with numerous megakaryocytes in the bone marrow, but without anemia or leukopenia, after taking procainamide (3 g/day) for a period of 2 months."	7.67	Procainamide-induced thrombocytopenia. ( Kosfeld, RE; Leight, L; Liu, YK; Rosenstein, R, 1984)
"From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])."	7.66	Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982)
"Thrombocytopenia developed in 23 patients with rheumatoid arthritis treated with gold salts over 25 years."	7.66	Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. ( Coblyn, JS; Glass, D; Holdsworth, D; Weinblatt, M, 1981)
"A case of a 52-year-old white woman who developed hemolytic anemia and thrombocytopenia after receiving D-penicillamine is presented."	7.65	Hemolytic anemia and thrombocytopenia associated with penicillamine ingestion. ( Harrison, EE; Hickman, JW, 1975)
"Sirolimus is an effective and safe treatment option for refractory CTD-TP patients."	7.01	Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. ( Li, M; Wang, Q; Wu, C; Xu, D; Zeng, X, 2021)
"Treatment with prednisone alone results in fewer infections and better survival than prednisone and azathioprine in standard-risk chronic GVHD."	6.66	Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. ( Appelbaum, FR; Dahlberg, S; Deeg, HJ; Doney, KC; Flournoy, N; Sanders, JE; Storb, R; Sullivan, KM; Weiden, P; Witherspoon, RP, 1988)
"Thrombocytopenia was the most frequent form of toxicity."	6.65	Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. ( Alexanian, R; Amare, M; Bonnet, J; Bottomley, R; Dixon, D; Haut, A; Salmon, S, 1982)
"TAFRO syndrome is a rare systemic inflammatory disease characterized by thrombocytopenia, pleural effusion, fever, renal dysfunction, reticulin fibrosis of the bone marrow, and organomegaly."	6.55	Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide. ( Abe, R; Kikuchi, T; Okamoto, S; Shimizu, T; Toyama, T, 2017)
"First-line AZA plus prednisone realizes a better hematological response and relapse-free duration with acceptable adverse events compared to prednisone alone in ANA-positive ITP patients."	5.91	Efficacy and safety of azathioprine plus prednisone versus prednisone alone as first-line treatment for antinuclear antibody-positive immune thrombocytopenia: a retrospective cohort study. ( Chen, X; Dong, Z; Ma, L; Su, J; Wang, Q; Xiao, P; Xu, M, 2023)
"Tranexamic acid was extremely well tolerated in this newborn."	5.28	Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants. ( Bernstein, M; Hanna, BD, 1989)
"Frentizole, an immunosuppressive phenylurea agent, used in a dosage of 4 mg/kg per day, was found to produce quick elevation of platelet counts in three thrombocytopenic patients."	5.26	Frentizole therapy of thrombocytopenia in systemic lupus erythematosus and refractory idiopathic thrombocytopenic purpura. ( Colgan, JP; Ferguson, RH; O'Duffy, JD; Phyliky, RL, 1980)
" After administration of the smaller dosage of prednisone, the mean vessel wall thickness increased to 3,556+/-40 A (P < 0."	5.26	Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit. ( Kitchens, CS, 1977)
"Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation."	5.19	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. ( Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R, 2014)
"The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)."	5.16	Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. ( Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2012)
"Initial analysis of the combination melphalan, prednisone, plus lenalidomide (MPR) showed significant antimyeloma activity in patients with untreated multiple myeloma, with neutropenia and thrombocytopenia as the most frequent side effects."	5.14	Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. ( Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB, 2009)
"A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients."	5.13	A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. ( Alinari, L; Baccarani, M; Bacci, F; Castellucci, P; de Vivo, A; Derenzini, E; Fanti, S; Farsad, M; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL, 2008)
"Antenatal therapy with intravenous immunoglobulin (IVIG) and prednisone has been shown to improve fetal thrombocytopenia and reduce the incidence of intracranial hemorrhage in neonatal alloimmune thrombocytopenia."	5.12	Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. ( Berkowitz, RL; Bussel, JB; Kolb, EA; Lesser, M; McFarland, JG; Primani, A; Wissert, M, 2006)
"In this prospective multicenter study of 73 women with documented alloimmune thrombocytopenia, patients were randomized to receive either intravenous immunoglobulin (IVIG) 2 g/kg/wk (group A) or IVIG 1 g/kg/wk plus prednisone 0."	5.12	Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. ( Berkowitz, RL; Bussel, JB; Hung, C; Lesser, ML; McFarland, JG; Primiani, A; Wissert, M, 2007)
"To evaluate the effect of prednisone alone, compared with a combination of prednisone and vincristine, on platelet counts in bleeding dogs with severe primary immune-mediated thrombocytopenia (IMT)."	5.10	Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs. ( Callan, MB; Giger, U; Hughes, D; Rozanski, EA; Sanders, N, 2002)
"Results of previous studies have suggested that transplantation-related mortality among patients with chronic graft-versus-host disease (GVHD) may be reduced by combined treatment with cyclosporine (CSP) and prednisone rather than by prednisone alone."	5.10	Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. ( Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP, 2002)
"Our study assessed the factors that predispose renal transplant recipients to the occurrence of thrombocytopenia and leukopenia, as well as the severity and the time- and concentration-dependence of these side-effects, after administration of sirolimus (SRL) in combination with a cyclosporine (CsA) and prednisone (Pred) regimen."	5.09	Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. ( Hong, JC; Kahan, BD, 2000)
"The objective was to assess the efficacy of therapy with danazol in refractory immune thrombocytopenia associated with different rheumatic diseases."	5.08	Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. ( Blanco, R; González-Gay, MA; Martinez-Taboada, VM; Rodriguez-Valverde, V; Sanchez-Andrade, A, 1997)
"Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)."	5.05	Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982)
"A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0."	5.05	Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982)
"Ninety-six patients with advanced chronic lymphocytic leukemia (CLL) (Stage C; anemia and/or thrombocytopenia of nonimmune origin) were randomized to receive either chlorambucil (CLR) (0."	5.05	Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. ( Alcalá, A; Bueno, J; Domingo, A; Ferrán, C; García-Conde, J; Giralt, M; Montserrat, E; Parody, R; Rubio, D; Sanz, MA, 1985)
"The aim of the present study was to investigate the relationship between hypothyroidism and thrombocytopenia in hepatitis B-related compensatory liver cirrhosis and to determine whether treatment with levothyroxine and prednisone is superior in a multicenter, open-label, observational study in China."	3.88	Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. ( Feng, R; Fu, H; Huang, X; Jiang, H; Jiang, Q; Liu, H; Liu, K; Lu, J; Niu, T; Wang, H; Wang, J; Wang, X; Xie, Y; Xu, L; Xue, J; Zhang, X, 2018)
" Her major chronic illness was immune thrombocytopenic purpura (ITP) for which she had been treated with prednisone therapy for the past 15 years."	3.80	From prednisone to pylori: a case of Helicobacter pylori-induced chronic immune thrombocytopenia. ( Hill, LJ; Tung, EE, 2014)
" We report a case of acute kidney injury (AKI) after treatment with a combination of oxaliplatin, folinic acid and 5-fluorouracil or capecitabine."	3.78	A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin. ( Imai, E; Ito, I; Ito, Y; Kosugi, T; Maruyama, S; Matsuo, S; Mizuno, M; Ozaki, T; Sato, W; Suzuki, Y; Tsuboi, N; Yasuda, K; Yasuda, Y, 2012)
"A total of 18 patients with newly diagnosed/untreated MM and renal insufficiency (GFR < 35 ml/min) were treated with bendamustine, prednisone, and bortezomib (BPV)."	3.78	Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. ( Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T, 2012)
" The patient underwent therapy with prednisone and heparin but developed heparin-induced thrombocytopenia."	3.77	Hypereosinophilic syndrome with cardiac involvement in a pregnant patient with multiple sclerosis. ( Darki, A; Jacobs, W; Kodali, PP; McPheters, JP; Patel, MR; Virk, H, 2011)
" During the next pregnancy, fetal genotyping confirmed the presence of HPA-5b antigen; she was treated with weekly intravenous human immunoglobulin and oral prednisone."	3.76	Fetal genotyping for platelets antigens: a precise tool for alloimmune thrombocytopenia: case report and literature review. ( Barini, R; Barjas-Castro, ML; Castro, V; Couto, E; Martinelli, BM; Nomura, ML; Passini Júnior, R, 2010)
" In those who do not respond, splenectomy is relatively ineffective and more specific anti-CMV treatment with ganciclovir is of unproven efficacy and toxic, in view of the relatively favourable long term outcome the authors recommend intravenous immunoglobulin in cases of severe bleeding or when the platelet level is under 10 x 10(9) l."	3.73	Cytomegalovirus-induced thrombocytopenia in an immunocompetent adult effectively treated with intravenous immunoglobulin: a case report and review. ( Alliot, C; Barrios, M, 2005)
" She was treated early in pregnancy with high-dose oral prednisone and weekly intravenous immunoglobulin (IVIG) alternating with anti-D immune globulin, but laparoscopic splenectomy was indicated at 20 weeks' gestation because of thrombocytopenia."	3.73	Laparoscopic splenectomy for the treatment of refractory immune thrombocytopenia in pregnancy. ( Griffiths, J; Shapiro, AM; Sia, W; Tataryn, I; Turner, AR, 2005)
"Because of the high relapse rate, AIHA and Evans syndrome should be treated according to the class of autoantibodies, and with longer course of prednisone and cyclosporin and prophylaxis of infection."	3.72	[An analysis of relapse and risk factors of autoimmune hemolytic anemia and Evans syndrome]. ( Bai, J; Cao, YR; Cui, ZZ; Fu, R; He, GS; Liu, H; Qin, TJ; Shao, ZH; Shi, J; Wu, YH; Yang, CL; Yang, TY, 2003)
"We report that the use of alternate-day cyclosporine and prednisone improved the clinical course of a 6-year-old child with severe Evans syndrome."	3.69	Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone. ( Manno, CS; Rackoff, WR, 1994)
"Azathioprine, a thiopurine antimetabolite used in the treatment of immune-mediated thrombocytopenia in human beings and dogs, was used in 2 cases of immune-mediated thrombocytopenia in horses that failed to respond to corticosteroid therapy alone."	3.68	Azathioprine for treatment of immune-mediated thrombocytopenia in two horses. ( Beech, J; Cudd, TA; Gardner, SY; Humber, KA; Palmer, JE; Sommer, MM, 1991)
"We describe a patient with scleroderma who developed immune thrombocytopenia secondary to diclofenac on 2 occasions."	3.68	Diclofenac induced immune thrombocytopenia. ( Epstein, M; Stein, H; Vickars, L, 1990)
"21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks."	3.67	Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984)
"An 81-year-old female developed marked thrombocytopenia associated with numerous megakaryocytes in the bone marrow, but without anemia or leukopenia, after taking procainamide (3 g/day) for a period of 2 months."	3.67	Procainamide-induced thrombocytopenia. ( Kosfeld, RE; Leight, L; Liu, YK; Rosenstein, R, 1984)
" A course of prednisone resulted in resolution of the neutropenia and a disappearance of the cytotoxic antibody."	3.67	Neutropenia and thrombocytopenia: antibodies directed against circulating neutrophils and bone marrow myeloid progenitor cells (CFU-C). ( Boxer, LA; Dinter, R; Goldberg, J; Kirshner, JJ, 1986)
" Adequate control of thrombocytopenia could not be obtained with prednisone therapy, and splenectomy produced a clinical remission."	3.66	Recurrent thrombocytopenia following idiopathic thrombocytopenic purpura. The importance of platelet-bound IgG in establishing cause. ( Logue, GL; Rosse, WF; Shimm, DS, 1980)
"Ninety-five patients with advanced non-Hodgkin's lymphoma were treated with four courses of cyclophosphamide, adriamycin, vincristine and prednisone, with or without procarbazine [CHOP(P)] chemotherapy; either 150 rad total body irradiation (for "extensive" disease) or 3,500 rad local radiation therapy (for "limited" disease); and a final four courses of CHOP(P) chemotherapy."	3.66	Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. ( Appelbaum, FR; Bagley, CM; Dahlberg, S; Farewell, VT; Kadin, ME; Neiman, PE; Rudolph, RH; Sullivan, KM; Thomas, ED, 1983)
"From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])."	3.66	Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982)
"Thrombocytopenia developed in 23 patients with rheumatoid arthritis treated with gold salts over 25 years."	3.66	Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. ( Coblyn, JS; Glass, D; Holdsworth, D; Weinblatt, M, 1981)
"Nineteen patients with advanced non-Hodgkin's lymphoma resistant to previous chemotherapy were treated with combination chemotherapy consisting of lomustine (CCNU), cytarabine, and prednisone."	3.66	Salvage chemotherapy for non-Hodgkin's lymphoma. ( Khoo, RK; Ng, PR; Todd, D, 1982)
"A case of a 52-year-old white woman who developed hemolytic anemia and thrombocytopenia after receiving D-penicillamine is presented."	3.65	Hemolytic anemia and thrombocytopenia associated with penicillamine ingestion. ( Harrison, EE; Hickman, JW, 1975)
"Twenty-five patients with advanced metastatic breast cancer were treated with the combination of methotrexate 60 mg/M(2) and 5-fluorouracil 700 mg/M(2) intravenously on the first and eighth days, and cyclophosphamide 100 mg/M(2) and prednisone 40 mg/M(2) by mouth daily for the first 14 days of a 28-day cycle."	3.65	Cyclical combination chemotherapy for advanced breast carcinoma. ( Canellos, GP; Chabner, BA; Devita, VT; Gold, GL; Schein, PS; Young, RC, 1974)
"Sirolimus is an effective and safe treatment option for refractory CTD-TP patients."	3.01	Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. ( Li, M; Wang, Q; Wu, C; Xu, D; Zeng, X, 2021)
" Adverse events included neutropenia (92/76%), thrombocytopenia (70/10%) and leukopenia (65/50%)."	2.87	Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized ( Belch, A; Bosly, A; Bunworasate, U; Cavalli, F; Dascalescu, A; Drach, J; Farber, C; Huang, H; Masliak, Z; Novak, J; Pei, L; Robak, T; Rooney, B; Samoilova, O; van de Velde, H; Vilchevskaya, K; Zaucha, J, 2018)
" We aimed to explore the effectiveness and safety of low-dose prednisone or cyclosporine A (CsA) combined with nucleoside analog (NA) in patients with severe thrombocytopenia associated with HBV-related LC."	2.80	Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. ( Feng, R; Fu, HX; Hu, JD; Huang, XJ; Jiang, H; Jiang, M; Jiang, Q; Liu, H; Ma, H; Niu, T; Wang, H; Wang, JW; Wang, X; Wang, Z; Wei, L; Xie, YD; Xu, LP; Zhang, XH; Zhu, XL, 2015)
"Reduced dosage of G-CSF allows dose-dense chemotherapy scheduling, limits exposure to G-CSF and also represents an opportunity for cost savings."	2.79	Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen. ( Bonizzoni, E; Bosi, A; Fabbri, E; Kovalchuk, S; Perrone, T; Puccini, B; Rigacci, L, 2014)
"Lenalidomide therapy was continued indefinitely in patients exhibiting clinical benefit."	2.74	Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. ( Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S, 2009)
"Everolimus is a macrolide immunosuppressive agent with known consistent absorption."	2.72	Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. ( Abecassis, M; Calmus, Y; Fischer, L; Freeman, R; Klempnauer, J; Langnas, A; Levy, G; Mayer, D; Nashan, B; Neuhaus, P; Punch, J; Roberts, J; Rogiers, X; Samuel, D; Schmidli, H; Sloof, M; Tuttle-Newhall, E, 2006)
"In patients with advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades."	2.72	Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly ( Dreyling, M; Hiddemann, W; Hoster, E; Lengfelder, E; Nickenig, C; Pfreundschuh, M; Reiser, M; Trumper, L; Unterhalt, M; Wandt, H, 2006)
"Three patients had grade 3 infections."	2.71	Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. ( Dührsen, U; Kasper, C; Müller-Beissenhirtz, H; Nückel, H, 2005)
" The distribution of adverse prognostic factors was comparable in the two-induction arm."	2.70	Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. ( Bernard, M; Casassus, P; Delain, M; Desablens, B; Guilhot, F; Hunault-Berger, M; Ifrah, N; Jouet, JP; Milpied, N; Sadoun, A, 2001)
"The best treatment of follicular lymphoma remains to be determined because the long natural history of follicular lymphoma requires mature data for accurate analysis."	2.70	Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma. ( Avilés, A; Cleto, S; Díaz, N; Díaz-Maqueo, JC; García, EL; Neri, N; Talavera, A, 2001)
"G-CSF can increase CDI in high-risk childhood ALL."	2.69	Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. ( Auclerc, MF; Auvrignon, A; Baruchel, A; Bauduer, F; Berthou, C; Bordigoni, P; Demeocq, F; Lamagnere, JP; Landman-Parker, J; Leblanc, T; Legall, E; Leverger, G; Mathey, C; Michel, G; Pautard, B; Perel, Y; Schaison, G; Schneider, P, 2000)
"Infections were seen more frequently in the 2-CdA+P-treated group (56%) than in the Chl+P-treated group (40%; P = ."	2.69	Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. ( Blasińska-Morawiec, M; Bloński, JZ; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Grieb, P; Hellmann, A; Kasznicki, M; Konopka, L; Kotlarek-Haus, S; Krykowski, E; Maj, S; Mrugala-Spiewak, H; Nowak, W; Potoczek, S; Robak, T; Skotnicki, AB; Urasiński, I; Zdziarska, B, 2000)
" Despite increased hematotoxicity, moderate dose escalation is safe for the majority of the patients with G-CSF assistance and standard supportive treatment."	2.69	Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). ( Diehl, V; Engel, C; Loeffler, M; Schmitz, S; Tesch, H, 2000)
" rhGM-CSF was administered at a dosage of 5 micrograms/kg for 10 days or until neutrophils were > 1/nl following chemotherapy."	2.68	Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study. ( Bergmann, L; Hoelzer, D; Karakas, T; Knuth, A; Lautenschläger, G; Mitrou, PS, 1995)
"Fifty-eight patients with previously untreated multiple myeloma were entered."	2.68	Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma. ( Gregory, SA; Greipp, PR; Kay, NE; Kyle, RA; O'Connell M, J; Oken, MM; Spiegel R, J; Tsiatis, A, 1996)
"Most hemangiomas are small, harmless birthmarks that appear soon after birth, proliferate for 8 to 18 months, and then slowly regress over the next 5 to 8 years, leaving normal or slightly blemished skin."	2.67	Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. ( Ezekowitz, RA; Folkman, J; Mulliken, JB, 1992)
"Treatment with prednisone alone results in fewer infections and better survival than prednisone and azathioprine in standard-risk chronic GVHD."	2.66	Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. ( Appelbaum, FR; Dahlberg, S; Deeg, HJ; Doney, KC; Flournoy, N; Sanders, JE; Storb, R; Sullivan, KM; Weiden, P; Witherspoon, RP, 1988)
"Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD)."	2.65	Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. ( Bond, WH; Chenoweth, L; Einhorn, LH; Stevens, EE; Williams, SD, 1983)
"Thrombocytopenia was the most frequent form of toxicity."	2.65	Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. ( Alexanian, R; Amare, M; Bonnet, J; Bottomley, R; Dixon, D; Haut, A; Salmon, S, 1982)
"TAFRO syndrome is a rare systemic inflammatory disease characterized by thrombocytopenia, pleural effusion, fever, renal dysfunction, reticulin fibrosis of the bone marrow, and organomegaly."	2.55	Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide. ( Abe, R; Kikuchi, T; Okamoto, S; Shimizu, T; Toyama, T, 2017)
"Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration."	2.53	[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016)
"Thrombocytopenia is rarely severe, and hemorrhage is far less common than thrombosis."	2.52	The significance and management of thrombocytopenia in antiphospholipid syndrome. ( Artim-Esen, B; Diz-Küçükkaya, R; İnanç, M, 2015)
"Immune thrombocytopenia is an autoimmune-mediated disorder and the treatment strategies were directed mainly to suppression of the immune system or to removal of the spleen as a place of thrombocyte destruction."	2.49	Contemporary treatment of immune thrombocytopenia. ( Bussel, JB; Izak, M, 2013)
"Severe neutropenia was defined as a neutrophil count <0."	2.42	Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. ( Font, J; Forns, X; García-Carrasco, M; Ingelmo, M; López-Guillermo, A; López-Medrano, F; Muñoz, C; Ramos-Casals, M; Trejo, O, 2003)
"The risk of preeclampsia and placental insufficiency was substantial and occurred in 50% of patients."	2.42	Antiphospholipid syndrome in obstetrics. ( Heilmann, L; Pollow, K; von Tempelhoff, GF, 2003)
"Evans syndrome is a rare disorder characterized by combined autoimmune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA)."	2.41	Allogeneic stem cell transplantation for Evans syndrome. ( Burt, RK; Miranda, M; Oyama, Y; Papadopoulos, EB; Traynor, AE, 2001)
"Leukopenia and thrombocytopenia are observed mostly as a side effect of therapy, particularly with use of immunosuppressive drugs."	2.40	Inflammatory bowel disease and immune thrombocytopenic purpura: is there a correlation? ( Ammirati, M; Gruenstein, S; Kim, P; Korelitz, BI; Lipsey, L; Schwarz, S; Wisch, N; Zlatanic, J, 1997)
"Prednisone was the most commonly used first-line therapy (75."	1.91	Immune Thrombocytopenia: Characteristics of the Population and Treatment Methods-One-Center Experience. ( Lebowa, W; Sacha, T; Zdziarska, J, 2023)
"First-line AZA plus prednisone realizes a better hematological response and relapse-free duration with acceptable adverse events compared to prednisone alone in ANA-positive ITP patients."	1.91	Efficacy and safety of azathioprine plus prednisone versus prednisone alone as first-line treatment for antinuclear antibody-positive immune thrombocytopenia: a retrospective cohort study. ( Chen, X; Dong, Z; Ma, L; Su, J; Wang, Q; Xiao, P; Xu, M, 2023)
"His labs were consistent with autoimmune haemolytic anaemia (AIHA), except his reticulocyte count was unexpectedly low."	1.56	Double hit: Evans syndrome after malignant thymoma treatment and parvovirus B19 infection. ( Atkinson, TS; Chaaya, G; Jetly-Shridhar, R; Xie, J, 2020)
"However, an association between ITP and influenza vaccination has not been firmly proven yet."	1.51	Epistaxis and gross haematuria with severe thrombocytopaenia associated with influenza vaccination. ( Abro, C; Almohammadi, A; Hrinczenko, B; Lundin, MS, 2019)
"Enterocytozoon bieneusi microsporidiosis is an emerging disease in immunocompromised patients."	1.46	Enterocytozoon bieneusi Microsporidiosis in Stem Cell Transplant Recipients Treated with Fumagillin ( Angoulvant, A; Bendib, I; Bonhomme, J; Bourhis, JH; Bukreyeva, I; Dargère, S; Gachot, B; Gagnard, JC; Thellier, M; Wyplosz, B, 2017)
"To evaluate the efficacy and adverse effects of low dose thalidomide (TD) combined with modified VCMP (vincristine+cyclophosphamide+melphalan+prednisone) (TD+mVCMP) and VAD (vincristine+doxorubicin+dexamethsone) (TD+VAD) regimens for treating aged patients with MM."	1.43	[Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. ( Liu, HB; Wang, W, 2016)
"DiGeorge syndrome is the most common chromosome microdeletion disease."	1.43	[Autoimmune disorder secondary to DiGeorge syndrome: a long-term follow-up case report and literature review]. ( Guo, JQ; Hua, Y; Lu, XT; Sun, Q; Xie, Y; Zhao, WH, 2016)
"Cabazitaxel (Cbz) is an approved second-line treatment in metastatic castration-resistant prostate cancer (mCRPC) following docetaxel therapy with a significant survival benefit compared with mitoxantrone."	1.39	Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. ( Albers, P; Arsov, C; Bokemeyer, C; Ecstein-Fraisse, E; Gschwend, J; Heidenreich, A; Heinrich, E; Honecker, F; Keck, B; Miller, K; Müller, SC; Otremba, B; Pfister, D; Retz, M; Rogenhofer, S; Scholz, HJ; Steiner, U; Trojan, L; Volkmer, B; Wirth, M, 2013)
"Treatment with prednisone resulted in normal values after only 3 days."	1.37	Asymptomatic macrothrombocytopenia in a young pure-bred beagle dog: a case report. ( Abel, SJ; Bodié, K; Desmond, DJ; Fagerland, JA; Gagne, GD; Sramek, MK, 2011)
"An 8-yr-old girl with familial systemic lupus erythematosus and several severe manifestations, including persistent thrombocytopenia, rapidly progressive renal failure and hepatic failure is described."	1.35	Familial systemic lupus erythematosus with hypercalcemia. ( Bagga, A; Kohli, U; Lodha, R, 2008)
"Actinomycin D was administered at a median dosage of 0."	1.35	Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006). ( Bannink, EO; Hauptman, JG; Mullins, MN; Obradovich, JE; Sauerbrey, ML, 2008)
"Thrombocytopenia is associated with this syndrome and is thought to represent platelet destruction within the lesions."	1.35	Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia. ( Buck, LM; Kline, RM, 2009)
"Multicentric Castleman disease is a rare lymphoproliferative disorder of unknown cause."	1.33	Multifocal Castleman disease in pediatrics: case report. ( Baserga, M; Rosin, M; Schoen, M; Young, G, 2005)
"Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is characterized by an acquired immune defect that can cause autoimmune complications, including anemia and thrombocytopenia."	1.32	Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. ( Kyasa, MJ; Parrish, RS; Schichman, SA; Zent, CS, 2003)
"The diagnostic criteria for systemic lupus erythematosus (SLE) were not fulfilled either."	1.32	Late puerperal thrombohemorrhagic complications in a patient with antiphospholipid syndrome. ( Bladt, V; d'Amore, F; Laursen, B; Petersen, OB; Poulsen, LH; Steengaard-Pedersen, K, 2004)
"A patient with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is reported in whom persistent thrombocytopenia was interpreted as continuing active disease; thrombocytopenia resolved only after plasma exchange treatments were stopped."	1.31	Unintentional platelet removal by plasmapheresis. ( Chandler, LK; Duvall, DS; George, JN; Gilcher, RO; Perdue, JJ; Smith, JW; Vesely, SK, 2001)
"A giant cavernous hemangioma of the left arm with severe thrombocytopenia and consumptive coagulopathy was observed in a neonate."	1.30	Successful management with interferon alpha-2a after prednisone therapy failure in an infant with a giant cavernous hemangioma. ( Antimi, A; Calisti, A; Castello, MA; Clerico, A; Lubrano, R; Patti, G; Ragni, G; Todini, A, 1997)
"Sixteen patients with Hodgkin's disease were treated with MOPP/ABVD and filgrastim support between January 1992 and March 1994."	1.30	G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. ( Gustavsson, A, 1997)
" Episodes of rejection and steroid dosage requirements are decreased for up to 9."	1.30	Long-term results of total lymphoid irradiation in the treatment of cardiac allograft rejection. ( Hoppe, RT; Hunt, SA; Strober, S; Tate, DJ; Wolden, SL, 1997)
"Kaposiform hemangioendothelioma is a locally aggressive, endothelial-derived spindle cell neoplasm that occurs exclusively in infants and adolescents."	1.30	Kaposiform hemangioendothelioma: a locally aggressive vascular tumor. ( Ball, NJ; Beaubien, ER; Storwick, GS, 1998)
"Thrombocytopenia was refractory to any therapy."	1.30	[32-year-old patient with systemic lupus erythematosus, thrombocytopenia and ischemic cerebrovascular insult and antiphospholipid antibodies]. ( Demarmels Biasiutti, F; Rigamonti Wermelinger, V, 1999)
"Thrombocytopenia was in 13 cases due to immunization to HPA-1a, in one case to HPA-5b, and in one case to HPA-6b."	1.30	Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia. ( Kekomäki, R; Sainio, S; Teramo, K, 1999)
"Management of follicular lymphoma after chemotherapy failure has been controversial and has ranged from watchful waiting to high-dose chemotherapy."	1.30	Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study. ( Blanco, AI; Cabanillas, F; Cox, JD; Ha, CS; Tucker, SL, 1999)
"We report a 54-year-old patient with Hodgkin's disease who achieved a complete remission after combined modality treatment."	1.29	Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease. ( Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL, 1995)
"We report here the case of a high grade malignant lymphoma which was characterized by an immunophenotype typical for CD3-negative NK-cells (CD2+, CD3-, CD16+, CD56(+), CD57-)."	1.29	High grade malignant lymphoma with clinical characteristics and immunophenotype of natural killer cells. ( Fehr, J; Rüegg, R; Schleiffenbaum, B; Zimmermann, D, 1995)
"Twenty-six had idiopathic thrombocytopenic purpura (ITP), gave birth to 33 infants, of which 22 were by spontaneous vaginal delivery, eight by lower segment cesarean section, and two by forceps."	1.29	Risk of thrombocytopenia in the infants of mothers with idiopathic thrombocytopenia. ( al Herbish, AS; al-Mobaireek, K; al-Mofada, SM; al-Momen, AK; Kides, E; Osman, ME, 1994)
"Azathioprine treatment played only a minor role in the development of thrombocytopenia but patients with low (100-200 mio."	1.29	Bone marrow function during quadruple immunosuppressive therapy after renal transplantation. ( Heaf, J, 1993)
"Primary antiphospholipid antibody syndrome is rarely complicated by chorea, but should be taken into consideration in patients who do not fulfill the diagnostic criteria for SLE."	1.29	Chorea in primary antiphospholipid syndrome. ( Antonini, G; Masala, C; Morino, S; Zangari, P, 1996)
"Epidural hematoma is a rare cause of spinal cord compression, which usually provokes severe neurological deficits."	1.29	Cervical spontaneous epidural hematoma as a complication of non-Hodgkin's lymphoma. ( Carletti, S; Frondizi, D; Maira, G; Mastronardi, L; Spera, C, 1996)
"Kasabach-Merritt syndrome is a combination of thrombocytopenia, intravascular coagulation, and a rapid increase in the size of an angioma."	1.28	[Kasabach-Merritt syndrome in children]. ( Andry, P; Bodemer, C; Brunelle, F; de Prost, Y; Hubert, P; Nihoul-Fékété, C; Sebag, G; Teillac-Hamel, D, 1992)
"The traditional treatment for the thrombocytopenia has been steroid therapy followed by splenectomy if steroid therapy fails."	1.28	Human gammaglobulin use in the treatment of severe thrombocytopenia associated with sarcoidosis. ( Guzzi, LM; Hornstein, EH; Kucera, RF; Lillis, P, 1991)
"Tranexamic acid was extremely well tolerated in this newborn."	1.28	Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants. ( Bernstein, M; Hanna, BD, 1989)
"The significance of thrombocytopenia in systemic lupus erythematosus (SLE) is unclear."	1.27	The significance of thrombocytopenia in systemic lupus erythematosus. ( Gladman, DD; Miller, MH; Urowitz, MB, 1983)
"Four infants with large congenital cavernous hemangiomas and Kasabach-Merritt syndrome are described."	1.27	Kasabach-Merritt syndrome in infants. ( Esterly, NB, 1983)
"Twenty-three patients with metastatic breast carcinoma were induced with a complex systemic therapy regimen in an attempt to ascertain if a complete remission rate greater than 50% could be obtained with intensive drug exposure."	1.27	Short term high density systemic therapy for metastatic breast cancer. ( Carbone, PP; Davis, TE; Kline, JC; Love, RR; Palta, M; Tormey, DC, 1985)
"In one patient, acquired immunodeficiency syndrome (AIDS) developed 12 months after splenectomy, but none of the other patients have evidence of AIDS."	1.27	Splenectomy for immune thrombocytopenia related to human immunodeficiency virus. ( Ferguson, CM, 1988)
"Prednisone was administered to 134 patients (90 per cent) in whom a peak platelet count occurred at a median of eight days, at which time four distinct patterns of response became evident: 20 patients (15 per cent) achieved complete remission with platelet counts greater than 200 X 10(9)/I, and of these 13 relapsed; 46 (34 per cent) had incomplete remission with platelet counts between 100 and 200 X 10(9)/I, and of these 38 relapsed; 22 (17 per cent) had a partial remission with platelet counts between 50 and 100 X 10(9)/I, and 14 have relapsed; the remaining 46 (34 per cent) failed to respond to prednisone."	1.27	Results of treatment in immune thrombocytopenia. ( Dent, DM; Jacobs, P; Wood, L, 1986)
"Coincident hemophilia and idiopathic thrombocytopenia has been rarely observed."	1.27	Chronic thrombocytopenia in an immunodeficient patient with hemophilia A. ( Bergmann, L; Hach, V; Mitrou, P; Mueller-Eckhardt, C; Scharrer, I, 1985)
"Fourteen patients with systemic lupus erythematosus had splenectomies done between 1960 and 1982 for treatment of severe thrombocytopenia."	1.27	Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. ( Greipp, PR; Hall, S; McCormick, JL; McKenna, CH; Michet, CJ, 1985)
"A boy, born in 1975, developed severe aplastic anaemia in 1982."	1.27	Cyclosporine A in a case of refractory severe aplastic anaemia. ( Seip, M; Vidnes, J, 1985)
"Treatment with prednisone and vincristine led to a rise in the platelet count to 100,000/mm3 after two months with no change in the splenomegaly."	1.27	Autoimmune thrombocytopenia in sarcoidosis. ( Greenberg, BR; Lawrence, HJ, 1985)
"A 38-year-old male with proven Takayasu's arteritis presented, in a routine investigation, with thrombocytopenia, prolonged whole blood clotting time and activated partial thromboplastin time."	1.26	Anti-factor IX circulating anticoagulant and immune thrombocytopenia in a case of Takayasu's arteritis. ( Lucia, JF; Oliveros, A; Torres, A; Torres, M; Vazquez, C, 1980)
"One patient with Hodgkin's disease involving the liver is alive at 36 months with further therapy."	1.26	Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease. ( Gamble, JF; Loh, KK; Rodgers, RW; Shullenberger, CC, 1980)
"Autoimmune thrombocytopenia has been recognized as a distinct entity in the dog and cat."	1.26	Autoimmune thrombocytopenia in dogs and cats. ( Jain, NC; Switzer, JW, 1981)
"In patients with chronic lymphocytic leukemia and depressed platelet counts, it is important to discriminate between the thrombocytopenia due to bone marrow replacement with abnormal lymphocytes and that caused by increased peripheral destruction of platelets."	1.26	Peripheral destruction of platelets in chronic lymphocytic leukemia: recognition, prognosis and therapeutic implications. ( Longo, DL; Rubinstein, DB, 1981)
"Frentizole, an immunosuppressive phenylurea agent, used in a dosage of 4 mg/kg per day, was found to produce quick elevation of platelet counts in three thrombocytopenic patients."	1.26	Frentizole therapy of thrombocytopenia in systemic lupus erythematosus and refractory idiopathic thrombocytopenic purpura. ( Colgan, JP; Ferguson, RH; O'Duffy, JD; Phyliky, RL, 1980)
" After administration of the smaller dosage of prednisone, the mean vessel wall thickness increased to 3,556+/-40 A (P < 0."	1.26	Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit. ( Kitchens, CS, 1977)
"A patient with idiopathic thrombocytopenia purpura who was treated with high dosage corticosteroids for ten years, developed 18 separate lesions of avascular necrosis in 12 different bones."	1.26	Steroid induced avascular necrosis of bones in eighteen sites: a case report. ( Milgram, JW; Riley, LH, 1976)

Research

Studies (490)

Authors

Clinical Trials (23)

Trial Overview

Trial Outcomes

Event-free Survival (EFS) (Phase II)

Timeframe	Studies, this research(%)	All Research%
pre-1990	274 (55.92)	18.7374
1990's	68 (13.88)	18.2507
2000's	72 (14.69)	29.6817
2010's	58 (11.84)	24.3611
2020's	18 (3.67)	2.80

Authors	Studies
Feng, R	3
Liu, Y	1
Zhu, XL	2
Zhai, WY	1
He, Y	1
Fu, HX	2
Jiang, Q	3
Jiang, H	3
Lu, J	2
Liu, H	4
Wang, JW	2
Wang, H	3
Xie, YD	2
Ma, H	2
Huang, XJ	2
Zhang, XH	2
Lanis, A	1
Volochayev, R	1
Kleiner, DE	1
Vittal, A	1
Heller, T	1
Rider, LG	1
Shenoi, S	1
Su, K	1
Cheng, H	1
Jia, Z	1
Yuan, Y	1
Yang, H	1
Gao, Q	1
Jiang, Z	1
Wen, H	1
Jiang, J	1
Qu, S	1
Xu, Z	1
Qin, T	1
Li, B	1
Pan, L	1
Chen, J	1
Yan, X	2
Wu, J	1
Zhang, Y	1
Zhang, P	1
Gale, RP	1
Xiao, Z	1
Lebowa, W	1
Zdziarska, J	1
Sacha, T	1
Zhang, HL	1
Uticul, A	1
Xu, XW	1
Shi, YW	1
Ratajczak-Enselme, M	1
Mutoni, GC	1
Desmeules, J	1
Favet, L	1
Ing Lorenzini, K	1
Apps, C	1
Su, J	1
Xu, M	1
Dong, Z	1
Wang, Q	2
Ma, L	1
Xiao, P	1
Chen, X	1
Wang, L	1
Wu, S	1
Yu, G	1
Sui, X	1
Chu, X	1
Liu, X	1
Cruickshank, A	1
Koury, J	1
Couri, FS	1
Kandula, M	1
Xie, J	1
Chaaya, G	1
Jetly-Shridhar, R	1
Atkinson, TS	1
Ramos, JC	1
Sparano, JA	1
Chadburn, A	1
Reid, EG	1
Ambinder, RF	1
Siegel, ER	1
Moore, PC	1
Rubinstein, PG	1
Durand, CM	1
Cesarman, E	1
Aboulafia, D	1
Baiocchi, R	1
Ratner, L	1
Kaplan, L	1
Capoferri, AA	1
Lee, JY	2
Mitsuyasu, R	1
Noy, A	1
Tessoulin, B	1
Bouabdallah, K	1
Burroni, B	1
Lamy, T	1
Gressin, R	2
Cartron, G	1
Thieblemont, C	1
Sarkozy, C	1
Haioun, C	1
Casasnovas, O	1
Joubert, C	1
Gyan, E	1
Hermine, O	1
Le Gouill, S	1
Okello, CD	1
Omoding, A	1
Ddungu, H	1
Mulumba, Y	1
Orem, J	1
Ma, J	2
Fu, L	1
Chen, Z	1
Gu, H	1
Wu, R	1
Goss, MB	1
Munoz, FM	1
Ruan, W	1
Galván, NTN	1
O'Mahony, CA	1
Rana, A	1
Cotton, RT	1
Moreno, NF	1
Heczey, AA	1
Leung, DH	1
Goss, JA	1
Wu, C	1
Xu, D	1
Li, M	1
Zeng, X	1
Bukreyeva, I	1
Angoulvant, A	1
Bendib, I	1
Gagnard, JC	1
Bourhis, JH	1
Dargère, S	1
Bonhomme, J	1
Thellier, M	1
Gachot, B	1
Wyplosz, B	1
Kjeldsen-Kragh, J	1
Jbara, M	1
Bhogal, S	1
Bajaj, K	1
Chhabra, L	1
Lee, SY	1
Hahm, JE	1
Ha, JW	1
Kim, CW	1
Kim, SS	1
Ergen, EN	1
Zwerner, JP	1
Kikuchi, T	1
Shimizu, T	1
Toyama, T	1
Abe, R	1
Okamoto, S	1
Maeda, Y	1
Nishimori, H	1
Yoshida, I	1
Hiramatsu, Y	1
Uno, M	1
Masaki, Y	1
Sunami, K	1
Masunari, T	1
Nawa, Y	1
Yamane, H	1
Gomyo, H	1
Takahashi, T	1
Yano, T	1
Matsuo, K	1
Ohshima, K	1
Nakamura, S	1
Yoshino, T	1
Tanimoto, M	1
Drach, J	2
Huang, H	2
Samoilova, O	1
Belch, A	1
Farber, C	1
Bosly, A	1
Novak, J	1
Zaucha, J	1
Dascalescu, A	1
Bunworasate, U	1
Masliak, Z	1
Vilchevskaya, K	1
Robak, T	2
Pei, L	1
Rooney, B	1
van de Velde, H	1
Cavalli, F	2
Xue, J	1
Fu, H	1
Wang, J	1
Niu, T	2
Wang, X	2
Xie, Y	2
Xu, L	1
Liu, K	1
Huang, X	1
Zhang, X	1
Kaya, Z	1
Egritas, O	1
Dalgic, B	1
Nakayama, S	1
Matsuda, M	1
Adachi, T	1
Sueda, S	1
Ohashi, Y	1
Awaji, S	1
Hashimoto, S	1
Matsumura, I	1
Almohammadi, A	1
Lundin, MS	1
Abro, C	1
Hrinczenko, B	1
Levin, C	1
Rozemman, D	1
Sakran, W	1
Halevy, R	1
Peleg, S	1
Koren, A	1
Rancea, M	1
Will, A	1
Borchmann, P	1
Monsef, I	1
Engert, A	2
Skoetz, N	1
Hegerova, LT	1
Lin, Y	1
Izak, M	1
Bussel, JB	5
Palumbo, A	3
Bringhen, S	1
Larocca, A	2
Rossi, D	1
Di Raimondo, F	1
Magarotto, V	2
Patriarca, F	1
Levi, A	1
Benevolo, G	2
Vincelli, ID	1
Grasso, M	1
Franceschini, L	1
Gottardi, D	1
Zambello, R	1
Montefusco, V	1
Falcone, AP	1
Omedé, P	1
Marasca, R	2
Morabito, F	2
Mina, R	1
Guglielmelli, T	1
Nozzoli, C	1
Passera, R	1
Gaidano, G	1
Offidani, M	2
Ria, R	1
Petrucci, MT	2
Musto, P	1
Boccadoro, M	3
Cavo, M	1
Rigacci, L	1
Puccini, B	1
Kovalchuk, S	1
Fabbri, E	1
Bonizzoni, E	1
Perrone, T	1
Bosi, A	1
Cavalli, G	1
Guglielmi, B	1
Ponzoni, M	1
Tresoldi, M	1
Dagna, L	1
Cachia, D	1
Izzy, S	1
Berriosmorales, I	1
Ionete, C	1
Hill, LJ	1
Tung, EE	1
Levy, R	1
Mahévas, M	1
Galicier, L	1
Boutboul, D	1
Moroch, J	1
Loustau, V	1
Guillaud, C	1
Languille, L	1
Fain, O	1
Bierling, P	1
Khellaf, M	1
Michel, M	1
Oksenhendler, E	1
Godeau, B	2
Xu, LP	1
Hu, JD	1
Jiang, M	1
Wang, Z	1
Wei, L	1
Artim-Esen, B	1
Diz-Küçükkaya, R	1
İnanç, M	1
Cohen, JB	1
Switchenko, JM	1
Koff, JL	1
Sinha, R	1
Kaufman, JL	1
Khoury, HJ	1
Bumpers, N	1
Colbert, A	1
Hutchison-Rzepka, A	1
Nastoupil, LJ	1
Heffner, LT	1
Langston, AA	1
Lechowicz, MJ	1
Lonial, S	1
Flowers, CR	1
Failing, JJ	1
Higgins, JV	1
Kautz, JM	1
Adam, Z	1
Pour, L	1
Krejčí, M	1
Ševčíková, S	1
Pourová, E	1
Ševčíková, E	1
Král, Z	1
Mayer, J	1
Carli, G	1
Visco, C	1
Falisi, E	1
Perbellini, O	1
Novella, E	1
Giaretta, I	1
Ferrarini, I	1
Sandini, A	1
Alghisi, A	1
Ambrosetti, A	1
Rodeghiero, F	1
Sriskandarajah, P	1
Davies, R	1
Wang, W	2
Liu, HB	1
Guo, JQ	1
Hua, Y	1
Zhao, WH	1
Sun, Q	1
Lu, XT	1
Regunath, H	1
Rojas-Moreno, C	1
Olano, JP	1
Hammer, RD	1
Salzer, W	1
Rama Kishore, Y	1
Prashantha, B	1
Girish, M	1
Manaswitha, B	1
Kohli, U	1
Lodha, R	1
Bagga, A	1
Bannink, EO	1
Sauerbrey, ML	1
Mullins, MN	1
Hauptman, JG	1
Obradovich, JE	1
Kline, RM	1
Buck, LM	1
Falco, P	1
Falcone, A	1
Canepa, L	1
Gay, F	1
Gozzetti, A	1
Luraschi, A	1
Nozza, A	1
Knight, RD	1
Zeldis, JB	1
Maio, P	1
Leone, S	1
Volpe, S	1
dell'Aquila, G	1
Giglio, S	1
Magliocca, M	1
Nigro, FS	1
Pacifico, P	1
Acone, N	1
Quintás-Cardama, A	1
Kantarjian, HM	1
Manshouri, T	1
Thomas, D	1
Cortes, J	1
Ravandi, F	1
Garcia-Manero, G	1
Ferrajoli, A	1
Bueso-Ramos, C	1
Verstovsek, S	1
Machaczka, M	1
Lerner, R	1
Klimkowska, M	1
Hägglund, H	1
Sternberg, CN	1
Petrylak, DP	1
Sartor, O	1
Witjes, JA	1
Demkow, T	1
Ferrero, JM	1
Eymard, JC	1
Falcon, S	1
Calabrò, F	1
James, N	1
Bodrogi, I	1
Harper, P	1
Wirth, M	2
Berry, W	1
Petrone, ME	1
McKearn, TJ	1
Noursalehi, M	1
George, M	1
Rozencweig, M	1
Aksu, K	1
Cagirgan, S	1
Ozsan, N	1
Keser, G	1
Sahin, F	1
Nomura, ML	1
Couto, E	1
Martinelli, BM	1
Barjas-Castro, ML	1
Barini, R	1
Passini Júnior, R	1
Castro, V	1
Osterborg, A	1
Karlsson, C	1
Lundin, J	1
Sidi, R	1
Rodak, R	1
Stüssi, G	1
Hara, T	1
Tsurumi, H	1
Kasahara, S	1
Ogawa, K	1
Takada, J	1
Imai, K	1
Takai, K	1
Kitagawa, J	1
Kiyama, S	1
Imai, N	1
Oyama, M	1
Takami, T	1
Moriwaki, H	1
Wang, DP	1
Liang, MY	1
Wang, SM	1
Darki, A	1
Kodali, PP	1
McPheters, JP	1
Virk, H	1
Patel, MR	1
Jacobs, W	1
Rayment, R	1
Brunskill, SJ	1
Soothill, PW	1
Roberts, DJ	1
Murphy, MF	1
Lin, Z	1
Lin, X	1
Cai, Q	1
Xia, Z	1
Jiang, W	1
Grace, RF	1
Bennett, CM	1
Ritchey, AK	1
Jeng, M	1
Thornburg, CD	1
Lambert, MP	1
Neier, M	1
Recht, M	1
Kumar, M	1
Blanchette, V	2
Klaassen, RJ	1
Buchanan, GR	1
Kurth, MH	1
Nugent, DJ	1
Thompson, AA	1
Stine, K	1
Kalish, LA	1
Neufeld, EJ	1
Bodié, K	1
Gagne, GD	1
Sramek, MK	1
Desmond, DJ	1
Abel, SJ	1
Fagerland, JA	1
Dąbrowska, M	1
Krenke, R	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma[NCT01193842]	Phase 1/Phase 2	107 participants (Actual)	Interventional	2010-10-06	Completed
Sirolimus in Patients With Connective Tissue Disease Related Thrombocytopenia (CTD-TP): a Single-arm, Open-label Clinical Trial in China[NCT03688191]	Phase 4	20 participants (Anticipated)	Interventional	2017-09-21	Active, not recruiting
Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma[NCT05996185]	Phase 2	36 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma[NCT03586999]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2018-11-07	Active, not recruiting
A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS[NCT01063179]	Phase 3	511 participants (Actual)	Interventional	2006-05-31	Completed
A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for[NCT05218603]		100 participants (Anticipated)	Observational	2021-11-30	Recruiting
A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas[NCT00634179]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2008-02-29	Completed
Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)[NCT00352794]	Phase 2	40 participants (Actual)	Interventional	2006-07-07	Completed
Comparison of Gemcitabine, Oxaliplatin and Pegaspargase and Etoposide, Vincristine, Doxorubicin, Cyclophosphamide and Prednisone as First-line Chemotherapy in Patients With NK/T-cell Lymphoma：a Prospective Randomized Phase III Study[NCT02359162]	Phase 3	50 participants (Actual)	Interventional	2015-05-31	Terminated (stopped due to The study is out of date)
The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia[NCT03258866]	Phase 4	62 participants (Actual)	Interventional	2010-01-01	Completed
A Randomized Prospective Trial of Conversion to Everolimus Therapy From Calcineurin Inhibitor Based Maintenance Immunosuppression in Association With Mycophenolic Acid in Liver Transplantation: Examination of Impact on Long Term Renal Function.[NCT01936519]		24 participants (Actual)	Interventional	2013-12-16	Completed
Exploring Patient Engagement Patterns and Participation Trends in Mantle Cell Lymphoma Clinical Trials[NCT06049472]		500 participants (Anticipated)	Observational	2024-10-31	Not yet recruiting
A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia[NCT00194987]	Phase 2/Phase 3	102 participants (Actual)	Interventional	2001-04-30	Completed
[NCT00850512]	Phase 2	55 participants (Actual)	Interventional		Completed
Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia[NCT04529382]		78 participants (Anticipated)	Observational	2019-12-17	Enrolling by invitation
Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193]	Phase 2	20 participants (Anticipated)	Interventional	2006-08-31	Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494]	Phase 2	134 participants (Actual)	Interventional	1992-05-31	Completed
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473]	Phase 2	100 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease[NCT06046248]	Phase 2	25 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Treatment of Chronic Graft Versus Host Disease With Extracorporeal Photopheresis[NCT00048789]	Phase 2	25 participants	Interventional	2002-11-04	Completed
Azacitidine (AZA) Combined With N-Acetyl-L-cysteine (NAC) for Prolonged Isolated Thrombocytopenia (PIT) After Hematopoietic Stem Cell Transplantation (HSCT)[NCT05126004]	Phase 2	100 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
A Prospective Study of Patients With Isolated Thrombocytopenia Following Hematopoietic Stem Cell Transplantation[NCT02487563]	Phase 3	97 participants (Actual)	Interventional	2015-10-31	Completed
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839]	Phase 2	21 participants (Actual)	Interventional	2012-02-22	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The percentage of participants surviving without events (relapse or death) one year after starting treatment. (NCT01193842)
Timeframe: 1 year

Overall Survival (OS) (Phase II)

Intervention	percentage of participants (Number)
Phase II: VR-DA-EPOCH	75.6
Phase II: DA-R-EPOCH	82.2

The percentage of participants surviving one year after starting treatment. (NCT01193842)
Timeframe: 1 year

Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)

Intervention	percentage of participants (Number)
Phase II: VR-DA-EPOCH	77.6
Phase II: DA-R-EPOCH	86.7

"Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study.~In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH)." (NCT01193842)
Timeframe: Up to 6 months

Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)

Intervention	percentage of participants (Number)
Phase II: VR-DA-EPOCH	67.5
Phase II: DA-R-EPOCH	76.2

Recommended phase II dose of vorinostat is defined as the dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT (Phase I). Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Using a 3+3 design, the recommended phase II dose is defined as the level at which 0/6 or 1/6 patients experiences at dose-limiting toxicity in the first cycle. (NCT01193842)
Timeframe: 21 days

Change in CD8 Cell Counts (Phase I)

Intervention	Mg per day of Vorinostat (Number)
Phase I: VR-DA-EPOCH	300

Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts. (NCT01193842)
Timeframe: Baseline up to 12 months

Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)

Intervention	cells/mm^3 (Median)
	End of cycle 2	Treatment discontinuation	6-month follow-up	12-month follow-up
Phase I: VR-CHOP, Dose Level 1	-172	-81	-16	128
Phase I: VR-DA-EPOCH, Dose Level 1	35.5	-164.5	-56	604
Phase I: VR-DA-EPOCH, Dose Level 2	-115	211	275	154

Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months

Changes in Absolute CD4 Cell Counts (Phase I)

Intervention	copies per milliliter (Median)
	End of cycle 2	Treatment discontinuation	6-month follow-up	12-month follow-up
Phase I: VR-CHOP, Dose Level 1	28	0	0	0
Phase I: VR-DA-EPOCH, Dose Level 1	-14518	-4517	-55116	0
Phase I: VR-DA-EPOCH, Dose Level 2	-12.5	0	0	0

Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts. (NCT01193842)
Timeframe: Baseline up to 12 months

Changes in Epstein-Barr Virus (EBV) Viral Load

Intervention	cell/mm^3 (Median)
	End of cycle 2	Treatment discontinuation	6-month follow-up	12-month follow-up
Phase I: VR-CHOP, Dose Level 1	-218	-190	-175	-84
Phase I: VR-DA-EPOCH, Dose Level 1	92	-39	76	169
Phase I: VR-DA-EPOCH, Dose Level 2	-9	-29	31	31

Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

Changes in Human Herpes Virus (HHV)-8 Viral Load

Intervention	IU/mL (Median)
	End of Cycle 2	At treatment discontinuation	6-month follow-up	12-month follow-up
Phase I: VR-DA-EPOCH, Dose Level 1	0	0	0	0
Phase I: VR-DA-EPOCH, Dose Level 2	-2436.1	-1.92	-1.92	-1.15
Phase II, DA-R-EPOCH	0	-0.28	0	-2.7
Phase II, VR-DA-EPOCH	-0.61	-2.9	-1.55	-0.56

Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

Changes in Human Herpes Virus (HHV)-8 Viral Load

Intervention	copies per 100uL (Median)
	12-month follow-up
Phase II: VR-DA-EPOCH	0

Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

Changes in Human Immunodeficiency Virus (HIV) Viral Load

Intervention	copies per 100uL (Median)
	At treatment discontinuation	6-month follow-up	12-month follow-up
Phase II: DA-R-EPOCH	0	0	0

Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)

Intervention	median change in copies per mL (Median)
	End of Cycle 2	At treatment discontinuation	6-month follow-up	12-month follow-up
Phase II: DA-R-EPOCH	-25	-22.5	-18	-20
Phase II: VR-DA-EPOCH	-20	-87	-20	0

The percentage of participants with AEs and their worst severity will be tabulated for each treatment arm. If a participant has more than one AE, the most severe AE is analyzed. All adverse events will be assessed by the investigator from the first dose of protocol therapy through the post-treatment discontinuation visit. Participants are planned to be treated for a total of 6 cycles (21 day cycle length), or roughly 4 months. After this evaluation, assessment and reporting of AEs will only be required for all grade 5 AEs and any serious AE (SAE) that the investigator considers related to protocol therapy. (NCT01193842)
Timeframe: Up to 5 years

Pharmacokinetic Clearance (Phase I)

Intervention	percentage of participants (Number)
	Death	Life-threatening	Severe	Moderate	Mild
Phase II: DA-R-EPOCH	20.0	28.9	31.1	17.8	0
Phase II: VR-DA-EPOCH	28.9	37.8	20.0	8.9	2.2

Serial plasma samples for pharmacokinetic analysis were collected at 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion. Doxorubicin, etoposide, and vincristine concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The clearance was determined by dividing the drug-infusion rate by the steady-state concentrations, which was the average of the three time points. (NCT01193842)
Timeframe: 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion

Tumor Response (Phase I)

Intervention	Liter/hour (Mean)
	Doxorubicin	Etoposide	Vincristine
Phase I: VR-DA-EPOCH, Dose Level 1	78.6	3.0	22.4
Phase I: VR-DA-EPOCH, Dose Level 2	76.0	2.4	16.8

The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease (NCT01193842)
Timeframe: Up to 2 years post treatment

Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)

Intervention	percentage of participants (Number)
	Complete response	Partial Response
Phase I: Arm C (VR-CHOP) Dose Level 1	100	0
Phase I: VR-DA-EPOCH, Dose Level 1	83.3	16.7
Phase I: VR-DA-EPOCH, Dose Level 2	83.3	16.7

INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression. (NCT00634179)
Timeframe: Cycle 1 for MTD, following completion of therapy for CR, up to 24 weeks

An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria

Intervention	mg/m^2 (Number)
MTD of Bortezomib With Vincristine Capped at 1.5 mg	1.62

Response was assessed by computerized tomography (CT) after every 2 cycles of induction therapy, one time at least 4 weeks after completing induction (i.e., prior to maintenance), and then every 3 months while on maintenance therapy. At the conclusion of maintenance therapy, patients underwent one post-treatment scan, with further scans completed at the discretion of the treating physician. Positron emission tomography was permitted but only CT measurements were used to determine response. (NCT00634179)
Timeframe: Following completion of therapy, up to 2 years

Number of Patients With Objective Response (Complete and Partial Response + Hematological Improvement)

Intervention	participants (Number)
	Complete Response (CR)	Partial Response (PR)	Overall Response Rate (ORR)
Phase I: Induction	13	6	19
Phase II: Maintenance	19	10	29

Time to response defined as the time from start of therapy until the response criteria are fulfilled. Response duration defined as the time from response until relapse (progressive disease) or death. (NCT00352794)
Timeframe: 6 months

Recipient and Donor Genotyping for Selected Variants of CYP3A5, ABCB1 (MDR1), and CYP4A Genes

Intervention	Participants (Count of Participants)
Lenalidomide + Prednisone	14

A blood sample was obtained from recipients and donors to measure gene polymorphism effects on metabolism of calcineurin inhibitor and everolimus. The polymorphisms are represented as the number of SNP occurrences for the CYP3A5, ABCB1 (MDR1) gene, and CYP4A4*22 genes. (NCT01936519)
Timeframe: 2 years

Renal Function as Measured by 24 Hour Urine Creatinine Clearance

Intervention	Participants (Count of Participants)
	Recipient Genotypes : rs776746 (CYP3A5 gene)	Recipient Genotypes : rs1045642 (ABCB1 gene)	Recipient Genotypes : rs1128503 (ABCB1 gene)	Recipient Genotypes : rs2032582 (ABCB1 gene)	Recipient Genotypes : rs35599367 (CYP4A4*22 gene)	Donor Genotypes : rs776746 (CYP3A5 gene)	Donor Genotypes : rs1045642 (ABCB1 gene)	Donor Genotypes : rs1128503 (ABCB1 gene)	Donor Genotypes : rs2032582 (ABCB1 gene)	Donor Genotypes : rs35599367 (Cyp4A4*22)
Calcineurin Inhibitor and Mycophenolic Acid	11	6	7	1	1	3	1	0	0	0
Everolimus and Mycophenolic Acid	11	6	8	0	1	0	5	0	0	1

Renal Function was assessed by 24 hr urine collection creatinine clearance measured (mL/min). 24 Hr urine collection was assessed at baseline, 6 months, 1 year, and 2 years post transplant. (NCT01936519)
Timeframe: 6 months, 1 year, and 2 years

Renal Function as Measured by Cockcroft Gault Creatinine Clearance

Intervention	mL/min (Mean)
	24hr Urine Creatinine Clearance at 6 months	24hr Urine Creatinine Clearance at 1 year	24hr Urine Creatinine Clearance at 2 years
Calcineurin Inhibitor With Mycophenolic Acid	68.09	68.09	61.54
Everolimus With Mycophenolic Acid	70.75	86.8	90.63

The Cockcroft-Gault formula for estimating creatinine clearance was determined at 6 months, 1 year, and 2 years post transplant (NCT01936519)
Timeframe: 6 months, 1 year, and 2 years

Renal Function as Measured by Iothalamate Clearance

Intervention	mL/min/1.73m2 (Mean)
	Cockcroft Gault Creatinine Clearance at 6 months	Cockcroft Gault Creatinine Clearance at 1 year	Cockcroft Gault Creatinine Clearance at 2 years
Calcineurin Inhibitor and Mycophenolic Acid	79.84	86.84	80.85
Everolimus and Mycophenolic Acid	100.17	113.47	108.16

Iothalamate Clearance was assessed at 6 months, 1 year, and 2 years post transplant. (NCT01936519)
Timeframe: 6 months, 1 year, and 2 years

Renal Function as Measured by Modification of Diet in Renal Disease (MDRD) Estimated Glomerular Filtration Rate (eGFR)

Intervention	mL/min/1.73m2 (Mean)
	Iothalamate Clearance at 6 months	Iothalamate Clearance at 1 year	Iothalamate Clearance at 2 years
Calcineurin Inhibitor and Mycophenolic Acid	67.99	66.65	57.19
Everolimus and Mycophenolic Acid	74.23	104.01	79.41

Modification of Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR) was assessed at 6 months, 1 year, and 2 years post transplant. (NCT01936519)
Timeframe: 6 months, 1 year, and 2 years

Renal Function as Measured by Serum Creatinine Level

Intervention	mL/min/1.73 m2 (Mean)
	MDRD eGFR at 6 months	MDRD eGFR at 1 year	MDRD eGFR at 2 years
Calcineurin Inhibitor and Mycophenolic Acid	62.18	60.63	53.29
Everolimus and Mycophenolic Acid	81.27	88.01	87.37

Serum creatinine levels were assessed at 6 months, 1 year, and 2 years post transplant (NCT01936519)
Timeframe: 6 months, 1 year, and 2 years

Intracranial Hemorrhage: Number Occurring in Fetuses and Newborns of Mothers in Study

Intervention	mg/dL (Mean)
	Serum Creatinine at 6 months	Serum Creatinine at 1 year	Serum Creatinine at 2 years
Calcineurin Inhibitor and Mycophenolic Acid	1.29	1.29	1.51
Everolimus and Mycophenolic Acid	1.02	0.95	0.95

number of ICH assessed by fetal and neonatal ultrasound with MRI back up most commonly in utero so range from 20-40 weeks fo gestation (NCT00194987)
Timeframe: time of ICH (range 20-40 wks)

Number of Fetal Platelet Counts > 50,000/uL

Intervention	number of newborns with ICH (Number)
IVIG 1g/kg Twice Per Week	0
IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day	0

Number of Fetal Platelet Counts > 50,000/uL Among Those Who Underwent Fetal Blood Sampling and Had a Fetal Platelet Count Determined (NCT00194987)
Timeframe: 32 +/- 2 weeks

Number of Newborns With a Birth Platelet Count > 50,000/uL

Intervention	number newborns with >50,000 pats (Number)
IVIG 1g/kg Twice Per Week	44
IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day	43

this uses the birth platelet count of the fetuses from the study when they are born (NCT00194987)
Timeframe: 32-40 weeks (the endpoint is the birth which is not at the same number of weeks for all of the babies. This is why the weeks are not listed specifically eg week 40

Megakaryocyte Count

Intervention	number of newborns with >50,000 pets (Number)
IVIG 1g/kg Twice Per Week	48
IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day	47

The total number of megakaryocytes as well as the platelet-shedding megakaryocytes of bone marrow smears (per cm2) was counted and cross-checked by blinded observers. (NCT02487563)
Timeframe: Up to 4 weeks after the treatment

Number of Participants With Platelet Count Recovery

Intervention	cells/cm^2 (Median)
Experimental Group 1	6.7
Experimental Group 2	7.5
Control Group	3.3

Platelet response refers to a sustained increase (stable or increasing level) of at least 30×10E9/L independent of transfusion for 3 days. (NCT02487563)
Timeframe: Up to 4 weeks after the treatment

Complete Response

Intervention	Participants (Count of Participants)
Experimental Group 1	20
Experimental Group 2	22
Control Group	6

Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles

Overall Response Rate

Intervention	Percentage of Participants (Number)
FCR With Lenalidomide	45

Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles

Article	Year
Novel approach to decrease platelet exposure in a pediatric Jehovah Witness patient. Pediatric blood & cancer, 2019, Volume: 66, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Child; Cyclophosphamide; Cytarabine	2019
Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide. Internal medicine (Tokyo, Japan), 2017, Aug-15, Volume: 56, Issue:16 Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; E	2017
Contemporary treatment of immune thrombocytopenia. Expert review of hematology, 2013, Volume: 6, Issue:6 Topics: Antibodies, Monoclonal, Murine-Derived; Biocompatible Materials; Hemorrhage; Humans; Immunosuppressi	2013
Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmunity reviews, 2014, Volume: 13, Issue:10 Topics: Adolescent; Adult; Agammaglobulinemia; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Female	2014
The significance and management of thrombocytopenia in antiphospholipid syndrome. Current rheumatology reports, 2015, Volume: 17, Issue:3 Topics: Antiphospholipid Syndrome; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Prednisone; Thromb	2015
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. Vnitrni lekarstvi, 2016, Volume: 62, Issue:1 Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc	2016
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Current hematologic malignancy reports, 2009, Volume: 4, Issue:1 Topics: Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize	2009
Antenatal interventions for fetomaternal alloimmune thrombocytopenia. The Cochrane database of systematic reviews, 2011, May-11, Issue:5 Topics: Antigens, Human Platelet; Dexamethasone; Female; Fetal Diseases; Glucocorticoids; Humans; Immunoglob	2011
Childhood immune thrombocytopenia: a changing therapeutic landscape. Seminars in thrombosis and hemostasis, 2011, Volume: 37, Issue:7 Topics: Antibodies, Monoclonal, Murine-Derived; Autoimmune Diseases; Child; Child, Preschool; Dexamethasone;	2011
Evans syndrome in a patient with chromosome 22q11.2 deletion syndrome: a case report. Pediatric hematology and oncology, 2003, Volume: 20, Issue:2 Topics: Anemia, Hemolytic, Autoimmune; Atrophy; Autoimmune Diseases; Brain; Chromosome Deletion; Chromosomes	2003
Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine, 2003, Volume: 82, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Antivir	2003
Antiphospholipid syndrome in obstetrics. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2003, Volume: 9, Issue:2 Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Annexin A5; Antibodies, Anticardiolipin; Anticoagu	2003
Idiopathic thrombocytopenic purpura in adults: current issues for pathogenesis, diagnosis and management. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 3 Topics: Adult; Autoimmune Diseases; Combined Modality Therapy; Diagnosis, Differential; Hemorrhage; Humans;	2004
The spleen and thrombocytopenia. Clinics in haematology, 1983, Volume: 12, Issue:2 Topics: Blood Platelets; Humans; Immunoglobulin G; Phagocytosis; Platelet Count; Prednisone; Purpura, Thromb	1983
Thrombocytopenia in the newborn. Seminars in perinatology, 1983, Volume: 7, Issue:3 Topics: Autoantibodies; Autoimmune Diseases; Blood Platelets; Blood Transfusion; Disseminated Intravascular	1983
Systemic lupus erythematosus X: corticosteroid therapy and its complications. Maryland state medical journal, 1984, Volume: 33, Issue:5 Topics: Anemia, Hemolytic; Central Nervous System Diseases; Cushing Syndrome; Humans; Kidney Diseases; Lupus	1984
Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). Blood, 1982, Volume: 60, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide;	1982
Drug-induced platelet destruction. Seminars in thrombosis and hemostasis, 1982, Volume: 8, Issue:2 Topics: Binding Sites, Antibody; Blood Platelets; Cell Differentiation; Cell Migration Inhibition; Clot Retr	1982
Inflammatory bowel disease and immune thrombocytopenic purpura: is there a correlation? The American journal of gastroenterology, 1997, Volume: 92, Issue:12 Topics: Adolescent; Adult; Anemia; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Female; Hum	1997
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Allogeneic stem cell transplantation for Evans syndrome. Bone marrow transplantation, 2001, Volume: 28, Issue:9 Topics: Adrenal Cortex Hormones; Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Autoimmune Di	2001
Immune-mediated cytopenia following bone marrow transplantation. Case reports and review of the literature. Medicine, 1992, Volume: 71, Issue:2 Topics: Adult; Anemia, Hemolytic; Blotting, Southern; Bone Marrow Transplantation; Chromosome Mapping; Diagn	1992
Adult-onset cyclic bicytopenia: a case report and review of treatment of cyclic hematopoiesis. American journal of hematology, 1989, Volume: 30, Issue:3 Topics: Agranulocytosis; Blood Cell Count; Female; Humans; Lymphocytes; Middle Aged; Neutropenia; Periodicit	1989
Adrenal steroids in the treatment of malignant hematologic disease. The Medical clinics of North America, 1973, Volume: 57, Issue:5 Topics: Adrenal Cortex Hormones; Anemia, Hemolytic; Antineoplastic Agents; Glucocorticoids; Hodgkin Disease;	1973
Management of drug allergy. Modern treatment, 1968, Volume: 5, Issue:5 Topics: Anaphylaxis; Anemia, Hemolytic; Antigen-Antibody Reactions; Desensitization, Immunologic; Drug Erupt	1968
[Current therapeutic possibilities in idiopathic myelofibrosis. Observations on 47 cases]. La Clinica terapeutica, 1968, Apr-15, Volume: 45, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Androgens; Anemia; Busulfan; Drug Synergism; Female; Humans; Leukocy	1968
The treatment of chronic lymphocytic leukemia. Seminars in hematology, 1969, Volume: 6, Issue:4 Topics: Adrenal Cortex Hormones; Alkylating Agents; Anemia; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Ag	1969
[New principles of treatment in acute leukemia]. Ugeskrift for laeger, 1970, Apr-30, Volume: 132, Issue:18 Topics: Adolescent; Adult; Antineoplastic Agents; Central Nervous System Diseases; Child; Cyclophosphamide;	1970
Glucocorticoids in haematology. Acta medica Scandinavica. Supplementum, 1969, Volume: 500 Topics: Adult; Agranulocytosis; Anemia, Hemolytic, Autoimmune; Antibodies; Blood Cell Count; Blood Cells; Ch	1969

Article	Year
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood, 2020, 09-10, Volume: 136, Issue:11 Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count;	2020
Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T Annals of hematology, 2020, Volume: 99, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxor	2020
High-dose dexamethasone as a replacement for traditional prednisone as the first-line treatment in children with previously untreated primary immune thrombocytopenia: a prospective, randomized single-center study. International journal of hematology, 2020, Volume: 112, Issue:6 Topics: Child; Child, Preschool; Dexamethasone; Drug Substitution; Female; Humans; Infant; Male; Prednisone;	2020
Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. Rheumatology (Oxford, England), 2021, 06-18, Volume: 60, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Connective Tissue Diseases; Female; Glucocorticoids; Humans	2021
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica, 2017, Volume: 102, Issue:12 Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide;	2017
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica, 2017, Volume: 102, Issue:12 Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide;	2017
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica, 2017, Volume: 102, Issue:12 Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide;	2017
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica, 2017, Volume: 102, Issue:12 Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide;	2017
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized Leukemia & lymphoma, 2018, Volume: 59, Issue:4 Topics: Adult; Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Pro	2018
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:9 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;	2014
Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. Platelets, 2015, Volume: 26, Issue:7 Topics: Adult; Blood Coagulation Tests; China; Cyclosporine; Drug Therapy, Combination; Female; Hemorrhage;	2015
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. British journal of haematology, 2015, Volume: 171, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-F	2015
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study. Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:2 Suppl 1 Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosp	2016
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relations	2009
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Lin	2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy P	2009
Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leukemia & lymphoma, 2011, Volume: 52, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha	2011
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leukemia & lymphoma, 2012, Volume: 53, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose	2012
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-01, Volume: 21, Issue:9 Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphami	2003
Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. The oncologist, 2005, Volume: 10, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat	2005
[Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma]. Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophos	2005
Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. Annals of hematology, 2005, Volume: 84, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; D	2005
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma. Oncology, 2005, Volume: 69, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free	2005
Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstetrics and gynecology, 2006, Volume: 107, Issue:1 Topics: Adult; Autoimmune Diseases; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administratio	2006
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2006, Volume: 12, Issue:11 Topics: Adult; Cholesterol; Cholesterol, LDL; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Do	2006
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly Cancer, 2006, Sep-01, Volume: 107, Issue:5 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclopho	2006
Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstetrics and gynecology, 2007, Volume: 110, Issue:2 Pt 1 Topics: Adult; Anti-Inflammatory Agents; Antigens, Human Platelet; Cordocentesis; Drug Combinations; Female;	2007
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyc	2008
Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet (London, England), 1984, Feb-18, Volume: 1, Issue:8373 Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marro	1984
Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. Cancer, 1983, Apr-15, Volume: 51, Issue:8 Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot	1983
Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. Blood, 1984, Volume: 64, Issue:1 Topics: Adult; Antibiotics, Antineoplastic; Asparaginase; B-Lymphocytes; Brain Neoplasms; Clinical Trials as	1984
The comparison of total body irradiation vs chlorambucil and prednisone for remission induction of active chronic lymphocytic leukemia: an ECOG study. Part I: total body irradiation-response and toxicity. International journal of radiation oncology, biology, physics, 1981, Volume: 7, Issue:12 Topics: Agranulocytosis; Chlorambucil; Clinical Trials as Topic; Hematopoietic Stem Cells; Humans; Leukemia,	1981
Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Cancer treatment reports, 1982, Volume: 66, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials a	1982
A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. American journal of clinical oncology, 1982, Volume: 5, Issue:4 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clin	1982
Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. Cancer treatment reports, 1982, Volume: 66, Issue:3 Topics: Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therap	1982
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. Cancer, 1982, Nov-01, Volume: 50, Issue:9 Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female;	1982
The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood, 1981, Volume: 58, Issue:3 Topics: Aged; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukopenia; Lymphoma	1981
EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C	1994
Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubici	1995
Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: a prospective randomized clinical trial. The American journal of medicine, 1994, Volume: 97, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aged; Female; Humans; Immunoglobulins, Intravenous; Male; M	1994
Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study. European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil;	1993
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3 Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch	1996
Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study. European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:13-14 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Bl	1995
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma. Leukemia & lymphoma, 1996, Volume: 20, Issue:5-6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cycloph	1996
Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. American journal of obstetrics and gynecology, 1996, Volume: 174, Issue:5 Topics: Cerebral Hemorrhage; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fem	1996
Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. British journal of rheumatology, 1997, Volume: 36, Issue:10 Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Anticardiolipin; Arthrit	1997
Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:7 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid	2000
Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation, 2000, May-27, Volume: 69, Issue:10 Topics: Adolescent; Adult; Aged; Cadaver; Cohort Studies; Cyclosporine; Drug Therapy, Combination; Female; H	2000
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood, 2000, Oct-15, Volume: 96, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladri	2000
Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Platelets;	2000
Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Bone marrow transplantation, 2000, Volume: 26, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Purging; Cispl	2000
Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease. Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:2 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Combined Modality Ther	2001
Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. Leukemia, 2001, Volume: 15, Issue:6 Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols	2001
OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma. Leukemia & lymphoma, 2000, Volume: 40, Issue:1-2 Topics: Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau	2000
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma. Journal of hematotherapy & stem cell research, 2001, Volume: 10, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dr	2001
Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. Medical and pediatric oncology, 2001, Volume: 37, Issue:5 Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chil	2001
Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs. Journal of the American Veterinary Medical Association, 2002, Feb-15, Volume: 220, Issue:4 Topics: Animals; Blood Platelets; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Glucocorticoids; Ma	2002
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood, 2002, Jul-01, Volume: 100, Issue:1 Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Cyclosporine; Drug Administration Sched	2002
Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. The New England journal of medicine, 1992, May-28, Volume: 326, Issue:22 Topics: Disseminated Intravascular Coagulation; Drug Administration Schedule; Drug Resistance; Female; Head	1992
Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood, 1988, Volume: 72, Issue:2 Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Disea	1988
Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer, 1985, Nov-15, Volume: 56, Issue:10 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic	1985
Azathioprine in the treatment of Crohn's disease. The British journal of surgery, 1972, Volume: 59, Issue:10 Topics: Azathioprine; Clinical Trials as Topic; Colic; Crohn Disease; Humans; Leukopenia; Lymphoma; Placebos	1972
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party on Leu British journal of haematology, 1974, Volume: 27, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Asparaginase; Blood Platelets; Child; Clinical Trials as Topic	1974
[On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4]. Schweizerische medizinische Wochenschrift, 1972, Oct-28, Volume: 102, Issue:43 Topics: Carmustine; Chlorambucil; Cyclohexanes; Drug Resistance; Drug Synergism; Hodgkin Disease; Humans; Ni	1972
Evaluation of aniline mustard in patients with multiple myeloma. Cancer research, 1973, Volume: 33, Issue:5 Topics: Adult; Aged; Aniline Compounds; Female; Hematocrit; Humans; Leukocyte Count; Leukopenia; Male; Middl	1973
Clinical experience with antilymphocyte globulin (ALG) in renal transplantation. Transplantation proceedings, 1971, Volume: 3, Issue:1 Topics: Anaphylaxis; Antilymphocyte Serum; Azathioprine; Clinical Trials as Topic; Drug Synergism; Graft Rej	1971

prednisone and Thrombocytopenia

Research Excerpts

Research

Studies (490)

Authors

Clinical Trials (23)

Trial Overview

Trial Outcomes

Event-free Survival (EFS) (Phase II)

Overall Survival (OS) (Phase II)

Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)

Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)

Change in CD8 Cell Counts (Phase I)

Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)

Changes in Absolute CD4 Cell Counts (Phase I)

Changes in Epstein-Barr Virus (EBV) Viral Load

Changes in Human Herpes Virus (HHV)-8 Viral Load

Changes in Human Herpes Virus (HHV)-8 Viral Load

Changes in Human Immunodeficiency Virus (HIV) Viral Load

Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)

Pharmacokinetic Clearance (Phase I)

Tumor Response (Phase I)

Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)

An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria

Number of Patients With Objective Response (Complete and Partial Response + Hematological Improvement)

Recipient and Donor Genotyping for Selected Variants of CYP3A5, ABCB1 (MDR1), and CYP4A Genes

Renal Function as Measured by 24 Hour Urine Creatinine Clearance

Renal Function as Measured by Cockcroft Gault Creatinine Clearance

Renal Function as Measured by Iothalamate Clearance

Renal Function as Measured by Modification of Diet in Renal Disease (MDRD) Estimated Glomerular Filtration Rate (eGFR)

Renal Function as Measured by Serum Creatinine Level

Intracranial Hemorrhage: Number Occurring in Fetuses and Newborns of Mothers in Study

Number of Fetal Platelet Counts > 50,000/uL

Number of Newborns With a Birth Platelet Count > 50,000/uL

Megakaryocyte Count

Number of Participants With Platelet Count Recovery

Complete Response

Overall Response Rate

Reviews

Trials

Other Studies